Navigation Links
Shengtai Pharmaceutical Retains Grayling Global As Investor Relations Counsel
Date:8/4/2008

WEIFANG, Shandong, China, Aug. 4 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it has retained Grayling Global to lead a strategic communications program ("the IR program") to shareholders, the investment community and financial media.

As the investor relations counsel for Shengtai Pharmaceutical, Grayling Global will help raise the investment community's awareness of the Company's performance through timely corporate updates, direct communications with fund managers, financial media placements and investor conference presentations. "We are pleased to have a global IR network and its senior counselors with long standing healthcare and industrial track records to help us raise our financial profile and ensure the full understanding of our business model and exciting growth prospects," said Mr. Qingtai Liu, Chief Executive Officer of Shengtai Pharmaceutical. "We need to increase our visibility and expand our relationships with U.S. investors. As we are becoming a bigger company and planning to move onto main exchange, we believe Grayling Global is best suited to guide this investor relations process."

Grayling Global, a subsidiary of Huntsworth PLC (LSE: HNT), is headquartered in London, with offices in New York, Brussels, Bangkok, Singapore, Madrid, Moscow, Tel Aviv, Hong Kong, Istanbul, Los Angeles, Sacramento, Dublin, Edinburgh, Cardiff, Bristol, and Birmingham. The firm has over 200 consultants, focusing on first-class delivery in public affairs, public relations, investor relations and events management.

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharm
'/>"/>

SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shengtai Pharmaceutical, Inc. Appoints New CFO
2. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
3. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
4. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
5. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
6. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
7. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
8. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
9. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
10. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
11. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... NEWTOWN, Pa. , March 4, 2015 ... trials services and technology provider, today announced ... and 10 countries convened at its annual ... Spain to discuss the use ... development challenges. BioClinica,s eClinical technologies include: the ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
(Date:3/3/2015)... 03, 2015 Experts and industry insiders ... one event: the Alltech REBELation exploring innovation, inspiration and ... Now in its 31st year, Alltech’s annual international conference ... and the opportunity to join the REBELation at an ... 11:59 p.m. EST, at which point the standard early ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... in its 3rd edition., WASHINGTON, Aug. ... of Building Biotechnology, the definitive biotechnology industry,primer ... This new,edition adds over 100 pages of ... figures and tables, and many new case ...
... -- Record consolidated revenues of $14.9 million ... -- Record international revenues of $2.3 million - 49% growth ... million -- Secured $10 million credit facility - expands capital resources, -- Reported MIS ... ...
... hits key insulin and Apo AI(Milano), milestones, ... /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), a biotechnology company ... cardiovascular diseases, today announced its,2008 second quarter financial ... Program, - Submitted an Investigational ...
Cached Biology Technology:New Book on the Business of Biotechnology 2AtriCure Reports Record Second Quarter 2008 Financial Results 2AtriCure Reports Record Second Quarter 2008 Financial Results 3AtriCure Reports Record Second Quarter 2008 Financial Results 4AtriCure Reports Record Second Quarter 2008 Financial Results 5AtriCure Reports Record Second Quarter 2008 Financial Results 6AtriCure Reports Record Second Quarter 2008 Financial Results 7AtriCure Reports Record Second Quarter 2008 Financial Results 8SemBioSys announces second quarter 2008 financial and operational results 2SemBioSys announces second quarter 2008 financial and operational results 3SemBioSys announces second quarter 2008 financial and operational results 4SemBioSys announces second quarter 2008 financial and operational results 5SemBioSys announces second quarter 2008 financial and operational results 6SemBioSys announces second quarter 2008 financial and operational results 7SemBioSys announces second quarter 2008 financial and operational results 8SemBioSys announces second quarter 2008 financial and operational results 9SemBioSys announces second quarter 2008 financial and operational results 10SemBioSys announces second quarter 2008 financial and operational results 11SemBioSys announces second quarter 2008 financial and operational results 12SemBioSys announces second quarter 2008 financial and operational results 13
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... seeds produced by many tropical trees were probably once ingested ... dispersed the seeds over large distances. But gomphotheres were probably ... aren,t large-seeded plants also extinct? A new Smithsonian report to ... of the National Academy of Sciences during the week ...
... BUFFALO, N.Y. -- While Spider-Man is capturing the imagination ... are working intently to save a young boy,s life. ... a stockbroker from the Buffalo suburbs, discovered that his ... fatal. It strikes only boys, causing their muscles to ...
... rare type of cancer thought to derive from cells in ... one type of liver cell morphs into a totally different ... UCSF researchers triggered this kind of cellular transformationand caused tumors ... suggests that drugs that are able to target those genes ...
Cached Biology News:Have thieving rodents saved tropical trees? 2Deadly liver cancer may be triggered by cells changing identity, UCSF study shows 2Deadly liver cancer may be triggered by cells changing identity, UCSF study shows 3
... The Rotofor purification system with PowerPac 3000 ... protein separation and purification by liquid-phase isoelectric ... mini (18 ml) and standard (60 ml) ... electrode chambers, PowerPac 3000 power supply, 10 ...
... Bio-Rad Molecular Imager VersaDoc MP 4000 ... CCD based imaging system capable of ... methods, including fluorescence, chemiluminescence, densitometry, and ... illumination sources allow imaging of multiplexed ...
...
...
Biology Products: